Ending HIV in the United States Will Require a Substantial Financial Commitment
“What will it take to end HIV in the United States?” is a pressing question posed by public health officials, researchers, and policymakers alike. Population Data & Modeling Core Director Benjamin Linas seeks to answer that question by amplifying notable results from a simulation modeling study published by researchers at Johns Hopkins. In an editorial issued in the Annals of […]
Characterizing Initiation, Use, and Discontinuation of Extended-Release Buprenorphine in a Nationally Representative United States Commercially Insured Cohort
Medications for opioid use disorder (MOUD) are evidence-based treatments that help people reduce or stop using opioids. However, high discontinuation rates of MOUD pose a barrier to reducing opioid-related overdoses. Extended-release buprenorphine (XR-BUP) is a relatively new MOUD, approved in late 2017, that has the potential to increase retention because of its monthly dosing schedule. Currently, there is […]
CHERISH Awarded Five-year Center of Excellence Grant to Continue Substance Use Health Economics Research
The National Institute on Drug Abuse (NIDA) of the National Institutes of Health has awarded the Center for Health Economics of Treatment Interventions for Substance Use, HCV and HIV (CHERISH) a five-year grant to continue the Center’s activities as a national center of excellence. CHERISH was founded in 2015 as a multi-institutional center for health […]
Simulation Modeling Presents Opportunities To Support The Public Health Response To The Opioid Crisis In North America
Although there are several evidence-based cost-effective interventions for people with opioid use disorder (OUD), they are underutilized. Questions remain regarding intervention selection, and cost of service delivery. Simulation modeling offers an opportunity to support decision making to address the syndemic of opioid overdose, HIV, and hepatitis C (HCV). In an article recently published in the International Journal […]
USPSTF and CDC Recommend Expanded HCV Testing for All US Adults
The US Preventive Services Task Force (USPSTF) released a draft recommendation for hepatitis C (HCV) antibody and RNA screening in all adults ages 18 to 79. This is a departure from their current 2013 recommendation of risk-based screening, including people who inject drugs (PWID), and one-time screening in baby boomers born between 1945 and 1965. The recommendation […]
Buprenorphine for Opioid Use Disorder Lowers Overdose Risk in Commercially Insured Individuals
“Medications for opioid use disorder saves lives.” That’s the title and conclusion of a recent report by the National Academies of Sciences, Engineering and Medicine, based on a review of the scientific evidence. In a new study in Drug and Alcohol Dependence, CHERISH investigators Jake Morgan, Bruce Schackman and Benjamin Linas add to this evidence base by […]
NIH funds HEALing Communities Study in Four States
On April 18, the National Institute on Drug Abuse (NIDA) together with the Substance Abuse and Mental Health Services Administration (SAMHSA) announced research sites in four states will receive funding as part of the Helping to End Addiction Long-term (HEAL) Initiative HEALing Communities Study. Each state will engage stakeholders and researchers across 15 communities in their […]
Two New Publications Address Expanding Access to HCV Care Among People Who Inject Drugs
Hepatitis C Virus (HCV) is one of the leading causes of infectious disease deaths in the United States. Injection drug use is a common route of HCV transmission and the annual number of reported cases continues to rise due to the opioid epidemic. Previous HCV treatment regimens had severe side effects and limited efficacy, but […]
Engage with CHERISH
Submit a Consultation Request or Contact Us to learn more about how CHERISH can support your research or policy goals.